# Kossel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kossel

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.kosselmed.com
- Total disclosed funding: $87M
- Latest round: Series C (Sep 1, 2026)
- Investors on record: 12

## About

Based in Jiangsu, China, and founded in 2013, Kossel Medtech (Suzhou) Co., Ltd., trading as Kossel, operates as a developer of vascular interventional medical devices, committed to providing clinical system solutions. It has passed ISO13485 and GMP certification, and it has acquired more than 200 invention patents and over 70 PCT patents. In September 2026, Kossel raised CNY 400 million in Series C funding co-led by Shenzhen Capital Real Estate Fund and Jinyuan Kuntong Equity Investment Management, with participation from Chuangjing Capital, Lingang Frontier (Shanghai) Private Equity Fund Management, Suzhou Capital Group, SND Ventures Group, Jiangsu Suzhou New&Hi-Tech Venture Capital, In Capital and other investors.

The company mainly provides devices in the fields of peripheral intervention, cardiac electrophysiology and coronary intervention. Its main products include vena cava filter, peripheral vascular balloon dilatation catheter, cardiac radiofrequency ablation catheter, radial artery hemostat, adjustable curved mapping catheter, etc. The cardiac radiofrequency ablation catheters can be used for mapping, recording and pacing of intracardiac electrophysiological signals. Vena cava filters can be used to prevent pulmonary embolism.

The company generates revenue by developing vascular interventional medical devices.

The company will use the latest funding to expand production capacity, promote the research and development and global registration of core products such as peripheral intervention, coronary intervention, and cardiac electrophysiology, and deepen the company's strategic layout of platformization, ecosystemization and internationalization in the pan-vascular intervention field.

## Funding rounds

- Series C, Sep 1, 2026, $60M — SND Ventures Group, In Capital, Shenzhen Capital Real Estate Fund, Jinyuan Kuntong Equity Investment Management, Jiangsu Suzhou New&Hi-Tech Venture Capital, Suzhou Capital Group, Chuangjing Capital, Lingang Frontier (Shanghai) Private Equity Fund Management
- Series B, Apr 28, 2025, $14M — SND Ventures Group, Great Stone Capital
- Series B, Dec 25, 2023, $14M — Fortune Capital, SND Ventures Group, Suzhou International Development Venture Capital Holding, Medpark

## Investors

- Fortune Capital — Series B
- SND Ventures Group (https://capitalatlas.ai/funds/snd-ventures-group) — Series B, Series C
- Suzhou International Development Venture Capital Holding (https://capitalatlas.ai/funds/suzhou-international-development-venture-capital-holding) — Series B
- Medpark — Series B
- Great Stone Capital (https://capitalatlas.ai/funds/great-stone-capital) — Series B
- In Capital — Series C
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series C
- Jiangsu Suzhou New&Hi-Tech Venture Capital — Series C
- Suzhou Capital Group — Series C
- Chuangjing Capital (https://capitalatlas.ai/funds/chuangjing-capital) — Series C
- Lingang Frontier (Shanghai) Private Equity Fund Management (https://capitalatlas.ai/funds/lingang-frontier-shanghai-private-equity-fund-management) — Series C